TAZORAC (tazarotene) Gel, 0.05% (tazarotene) Gel, 0.1% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.
|
|
- Annice Fox
- 6 years ago
- Views:
Transcription
1 TAZORAC (tazartene) Gel, 0.05% (tazartene) Gel, 0.1% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. DESCRIPTION TAZORAC Gel is a translucent, aqueus gel and cntains the cmpund tazartene, a member f the acetylenic class f retinids. It is fr tpical dermatlgic use nly. The active ingredient is represented by the fllwing structural frmula: Frmula: C 21 H 21 NO 2 S Mlecular Weight: Chemical Name: Ethyl 6-[(4,4-dimethylthichrman-6-yl)ethynyl]nictinate Cntains: Active: Tazartene 0.05% r 0.1% (w/w) Preservative: Benzyl alchl 1% (w/w) Inactives: Ascrbic acid; butylated hydrxyanisle; butylated hydrxytluene; carbmer hmplymer type B; edetate disdium; hexylene glycl; plxamer 407; plyethylene glycl 400; plysrbate 40; purified water; and trmethamine. CLINICAL PHARMACOLOGY Tazartene is a retinid prdrug which is cnverted t its active frm, the cgnate carbxylic acid f tazartene (AGN ), by rapid deesterificatin in animals and man. AGN ( tazartenic acid ) binds t all three members f the retinic acid receptr (RAR) family: RARα, RARβ, and RARγ but shws relative selectivity fr RARβ, and RARγ and may mdify gene expressin. The clinical significance f these findings is unknwn. Psriasis: The mechanism f tazartene actin in psriasis is nt defined. Tpical tazartene blcks inductin f muse epidermal rnithine decarbxylase (ODC) activity, which is assciated with cell prliferatin and hyperplasia. In cell culture and in vitr mdels f skin, tazartene suppresses expressin f MRP8, a marker f inflammatin present in the epidermis f psriasis patients at high levels. In human keratincyte cultures, it inhibits crnified envelpe frmatin, whse build-up is an element f the psriatic scale. Tazartene als induces the expressin f a gene which may be a grwth suppressr in human keratincytes and which may inhibit epidermal hyperprliferatin in treated plaques. Hwever, the clinical significance f these findings is unknwn. Acne: The mechanism f tazartene actin in acne vulgaris is nt defined. Hwever, the basis f tazartene s therapeutic effect in acne may be due t its anti-hyperprliferative, nrmalizing-f-differentiatin and anti-
2 inflammatry effects. Tazartene inhibited crnecyte accumulatin in rhin muse skin and crss-linked envelpe frmatin in cultured human keratincytes. The clinical significance f these findings is unknwn. Pharmackinetics: Fllwing tpical applicatin, tazartene underges esterase hydrlysis t frm its active metablite, tazartenic acid. Little parent cmpund culd be detected in the plasma. Tazartenic acid was highly bund t plasma prteins (greater than 99%). Tazartene and tazartenic acid were metablized t sulfxides, sulfnes and ther plar metablites which were eliminated thrugh urinary and fecal pathways. The half-life f tazartenic acid was apprximately 18 hurs, fllwing tpical applicatin f tazartene t nrmal, acne r psriatic skin. The human in viv studies described belw were cnducted with tazartene gel applied tpically at apprximately 2 mg/cm 2 and left n the skin fr 10 t 12 hurs. Bth the peak plasma cncentratin (C max ) and area under the plasma cncentratin time curve (AUC) refer t the active metablite nly. Tw single, tpical dse studies were cnducted using 14 C-tazartene gel. Systemic absrptin, as determined frm radiactivity in the excreta, was less than 1% f the applied dse (withut cclusin) in six psriatic patients and apprximately 5% f the applied dse (under cclusin) in six healthy subjects. One nnradilabeled single-dse study cmparing the 0.05% gel t the 0.1% gel in healthy subjects indicated that the Cmax and AUC were 40% higher fr the 0.1% gel. After 7 days f tpical dsing with measured dses f tazartene 0.1% gel n 20% f the ttal bdy surface withut cclusin in 24 healthy subjects, the Cmax fr tazartenic acid was 0.72 ± 0.58 ng/ml (mean ± SD) ccurring 9 hurs after the last dse, and the AUC 0-24hr fr tazartenic acid was 10.1 ± 7.2 ng hr/ml. Systemic absrptin was 0.91 ± 0.67% f the applied dse. In a 14-day study in five psriatic patients, measured dses f tazartene 0.1% gel were applied daily by nursing staff t invlved skin withut cclusin (8 t 18% f ttal bdy surface area; mean ± SD: 13 ± 5%). The Cmax fr tazartenic acid was 12.0 ± 7.6 ng/ml ccurring 6 hurs after the final dse, and the AUC 0-24hr fr tazartenic acid was 105 ± 55 ng hr/ml. Systemic absrptin was 14.8 ± 7.6% f the applied dse. Extraplatin f these results t represent dsing n 20% f ttal bdy surface yielded estimates fr tazartenic acid with Cmax f 18.9 ± 10.6 ng/ml and AUC 0-24hr f 172 ± 88 ng hr/ml. An in vitr percutaneus absrptin study, using radilabeled drug and freshly excised human skin r human cadaver skin, indicated that apprximately 4 t 5% f the applied dse was in the stratum crneum (tazartene: tazartenic acid = 5:1) and 2 t 4% was in the viable epidermis-dermis layer (tazartene: tazartenic acid = 2:1) 24 hurs after tpical applicatin f the gel. Clinical Studies Psriasis: In tw large vehicle-cntrlled clinical studies, tazartene 0.05% and 0.1% gels applied nce daily fr 12 weeks were significantly mre effective than vehicle in reducing the severity f the clinical signs f stable plaque psriasis cvering up t 20% f bdy surface area. In ne f the studies, patients were fllwed up fr an additinal 12 weeks fllwing cessatin f therapy with TAZORAC Gel. Mean baseline scres and changes frm baseline (reductins) after treatment in these tw studies are shwn in the fllwing table:
3 Plaque Elevatin, Scaling, and Erythema in Tw Cntrlled Clinical Trials fr Psriasis Plaque Elevatin Scaling Erythema B* C-12* C-24* B* C-12* C-24* B* C-12* C-24* TAZORAC 0.05% Gel TAZORAC 0.1% Gel Vehicle Gel Trunk/Arm/Leg Lesins Knee/Elbw Lesins Trunk/Arm/Leg Lesins Knee/Elbw Lesins Trunk/Arm/Leg Lesins Knee/Elbw Lesins N=108 N=111 N=108 N= 111 N=108 N=112 N=108 N=112 N=108 N=113 N=108 N= Plaque elevatin, scaling, and erythema scred n a 0-4 scale with 0=nne, 1=mild, 2=mderate, 3=severe and 4=very severe. B*=Mean Baseline Severity: C-12*=Mean Change frm Baseline at end f 12 weeks f therapy: C-24*=Mean Change frm Baseline at week 24 (12 weeks after the end f therapy). Glbal imprvement ver baseline at the end f 12 weeks f treatment in these tw studies is shwn in the fllwing table: TAZORAC 0.05% Gel TAZORAC 0.1% Gel Vehicle Gel N=81 N=93 N=79 N=69 N=84 N=91 100% imprvement 2 (2%) 1 (1%) (1%) 0 75% imprvement 23 (28%) 17 (18%) 30 (38%) 17 (25%) 10 (12%) 9 (10%) 50% imprvement 42 (52%) 39 (42%) 51 (65%) 36 (52%) 28 (33%) 21 (23%) 1-49% imprvement 21 (26%) 32 (34%) 18 (23%) 23 (33%) 27 (32%) 32 (35%) N change r wrse 18 (22%) 22 (24%) 10 (13%) 10 (14%) 29 (35%) 38 (42%) The 0.1% gel was mre effective than the 0.05% gel, but the 0.05% gel was assciated with less lcal irritatin than the 0.1% gel (see ADVERSE REACTIONS sectin). Acne: In tw large vehicle-cntrlled studies, tazartene 0.1% gel applied nce daily was significantly mre effective than vehicle in the treatment f facial acne vulgaris f mild t mderate severity. Percent reductins in lesin cunts after treatment fr 12 weeks in these tw studies are shwn in the fllwing table: Reductin in Lesin Cunts after Twelve Weeks f Treatment in Tw Cntrlled Clinical Trials fr Acne TAZORAC 0.1% Gel Vehicle Gel N=150 N=149 N=148 N=149 Nninflammatry lesins 55% 43% 35% 27% Inflammatry lesins 42% 47% 30% 28% Ttal lesins 52% 45% 33% 27%
4 Glbal imprvement ver baseline at the end f 12 weeks f treatment in these tw studies is shwn in the fllwing table: TAZORAC 0.1% Gel Vehicle Gel N=105 N=117 N=117 N= % imprvement 1 (1%) % imprvement 40 (38%) 21 (18%) (10%) (20%) 50% imprvement 71 (68%) 56 (48%) (29%) (40%) 1-49% imprvement 23 (22%) 49 (42%) (42%) (41%) N change r wrse 11 (10%) 12 (10%) 22 (19%) 32 (29%) INDICATIONS AND USAGE TAZORAC (tazartene) Gel 0.05% and 0.1% are indicated fr the tpical treatment f patients with stable plaque psriasis f up t 20% bdy surface area invlvement. TAZORAC (tazartene) Gel 0.1% is als indicated fr the tpical treatment f patients with facial acne vulgaris f mild t mderate severity. The efficacy f TAZORAC Gel in the treatment f acne previusly treated with ther retinids r resistant t ral antibitics has nt been established. CONTRAINDICATIONS Retinids may cause fetal harm when administered t a pregnant wman. In rats, tazartene 0.05% gel, administered tpically during gestatin days 6 thrugh 17 at 0.25 mg/kg/day (1.5 mg/m 2 /day) resulted in reduced fetal bdy weights and reduced skeletal ssificatin. Rabbits dsed tpically with 0.25 mg/kg/day (2.75 mg/m 2 ttal bdy surface area/day) tazartene gel during gestatin days 6 thrugh 18 were nted with single incidences f knwn retinid malfrmatins, including spina bifida, hydrcephaly, and heart anmalies. Systemic daily-expsure (AUC de ) t tazartenic acid at tpical dses f 0.25 mg/kg/day tazartene in a gel frmulatin in rats and rabbits represented 0.62 and 6.7 times, respectively, the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 0.78 and 8.4 times, respectively, the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. As with ther retinids, when tazartene was given rally t experimental animals, develpmental delays were seen in rats, and teratgenic effects and pst-implantatin lss were bserved in rats and rabbits at AUC de values that were 0.55 and 13.2 times, respectively, the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 0.68 and 16.4 times, respectively, the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. In a study f the effect f ral tazartene n fertility and early embrynic develpment in rats, decreased number f implantatin sites, decreased litter size, decreased numbers f live fetuses, and decreased fetal bdy weights, all classic develpmental effects f retinids, were bserved when female rats were administered 2 mg/kg/day frm 15 days befre mating thrugh gestatin day 7. A lw incidence f retinid-related
5 malfrmatins at that dse was reprted t be related t treatment. This dse prduced an AUC de that was 1.7 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area) and 2.1 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. SYSTEMIC EXPOSURE TO TAZAROTENIC ACID IS DEPENDENT UPON THE EXTENT OF THE BODY SURFACE AREA TREATED. IN PATIENTS TREATED TOPICALLY OVER SUFFICIENT BODY SURFACE AREA, EXPOSURE COULD BE IN THE SAME ORDER OF MAGNITUDE AS IN THESE ORALLY TREATED ANIMALS. ALTHOUGH THERE MAY BE LESS SYSTEMIC EXPOSURE IN THE TREATMENT OF ACNE OF THE FACE ALONE DUE TO LESS SURFACE AREA FOR APPLICATION, TAZAROTENE IS A TERATOGENIC SUBSTANCE, AND IT IS NOT KNOWN WHAT LEVEL OF EXPOSURE IS REQUIRED FOR TERATOGENICITY IN HUMANS (SEE CLINICAL PHARMACOLOGY: PHARMACOKINETICS). There were thirteen reprted pregnancies in patients wh participated in clinical trials fr tpical tazartene. Nine f the patients were fund t have been treated with tpical tazartene, and the ther fur had been treated with vehicle. One f the patients wh was treated with tazartene cream elected t terminate the pregnancy fr nn-medical reasns unrelated t treatment. The ther eight pregnant wmen wh were inadvertently expsed t tpical tazartene during clinical trials subsequently delivered apparently healthy babies. As the exact timing and extent f expsure in relatin t the gestatin times are nt certain, the significance f these findings is unknwn. TAZORAC Gel is cntraindicated in wmen wh are r may becme pregnant. If this drug is used during pregnancy, r if the patient becmes pregnant while taking this drug, treatment shuld be discntinued and the patient apprised f the ptential hazard t the fetus. Wmen f child-bearing ptential shuld be warned f the ptential risk and use adequate birth-cntrl measures when TAZORAC Gel is used. The pssibility that a wman f child-bearing ptential is pregnant at the time f institutin f therapy shuld be cnsidered. A negative result fr pregnancy test having a sensitivity dwn t at least 50 miu/ml fr human chrinic gnadtrpin (hcg) shuld be btained within 2 weeks prir t TAZORAC Gel therapy, which shuld begin during a nrmal menstrual perid (see als PRECAUTIONS: Pregnancy: Teratgenic Effects). TAZORAC Gel is cntraindicated in individuals wh have shwn hypersensitivity t any f its cmpnents. WARNINGS See CONTRAINDICATIONS sectin. Wmen f child-bearing ptential shuld be warned f the ptential risk and use adequate birth-cntrl measures when TAZORAC Gel is used. The pssibility that a wman f childbearing ptential is pregnant at the time f institutin f therapy shuld be cnsidered. A negative result fr pregnancy test having a sensitivity dwn t at least 50 miu/ml fr hcg shuld be btained within 2 weeks prir t TAZORAC Gel therapy, which shuld begin during a nrmal menstrual perid. PRECAUTIONS General TAZORAC Gel shuld be applied nly t the affected areas. Fr external use nly. Avid cntact with eyes, eyelids, and muth. If cntact with eyes ccurs, rinse thrughly with water. The safety f use f TAZORAC Gel ver mre than 20% f bdy surface area has nt been established in psriasis r acne. Retinids shuld nt be used n eczematus skin, as they may cause severe irritatin.
6 Because f heightened burning susceptibility, expsure t sunlight (including sunlamps) shuld be avided unless deemed medically necessary, and in such cases, expsure shuld be minimized during the use f TAZORAC Gel. Patients must be warned t use sunscreens (minimum SPF f 15) and prtective clthing when using TAZORAC Gel. Patients with sunburn shuld be advised nt t use TAZORAC Gel until fully recvered. Patients wh may have cnsiderable sun expsure due t their ccupatin and thse patients with inherent sensitivity t sunlight shuld exercise particular cautin when using TAZORAC Gel and ensure that the precautins utlined in the Infrmatin fr Patients subsectin are bserved. TAZORAC Gel shuld be administered with cautin if the patient is als taking drugs knwn t be phtsensitizers (e.g., thiazides, tetracyclines, flurquinlnes, phenthiazines, sulfnamides) because f the increased pssibility f augmented phtsensitivity. Sme individuals may experience excessive pruritus, burning, skin redness r peeling. If these effects ccur, the medicatin shuld either be discntinued until the integrity f the skin is restred, r the dsing shuld be reduced t an interval the patient can tlerate. Hwever, efficacy at reduced frequency f applicatin has nt been established. Alternatively, patients with psriasis wh are being treated with the 0.1% cncentratin can be switched t the lwer cncentratin. Weather extremes, such as wind r cld, may be mre irritating t patients using TAZORAC Gel. Infrmatin fr Patients See attached Patient Package Insert. Drug Interactins Cncmitant dermatlgic medicatins and csmetics that have a strng drying effect shuld be avided. It is als advisable t "rest" a patient's skin until the effects f such preparatins subside befre use f TAZORAC Gel is begun. In a study f 27 healthy female subjects between the ages f years receiving a cmbinatin ral cntraceptive tablet cntaining 1 mg nrethindrne and 35 mcg ethynyl estradil, cncmitant use f tazartene did nt affect the pharmackinetics f nrethindrne and ethynyl estradil ver a cmplete cycle. The impact f tazartene n the pharmackinetics f prgestin nly ral cntraceptives (i.e., minipills) has nt been evaluated. Carcingenesis, Mutagenesis, Impairment f Fertility A lng-term study f tazartene fllwing ral administratin f 0.025, 0.050, and mg/kg/day t rats shwed n indicatins f increased carcingenic risks. Based n pharmackinetic data frm a shrter-term study in rats, the highest dse f mg/kg/day was anticipated t give systemic expsure (AUC de ) in the rat equivalent t 0.32 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 0.38 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. In evaluatin f pht c-carcingenicity, median time t nset f tumrs was decreased and the number f tumrs increased in hairless mice fllwing chrnic tpical dsing with intercurrent expsure t ultravilet radiatin at tazartene cncentratins f 0.001%, 0.005%, and 0.01% in a gel frmulatin fr up t 40 weeks. A lng-term tpical applicatin study f up t 0.1% tazartene in a gel frmulatin in mice terminated at 88 weeks shwed that dse levels f 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced t 0.5 mg/kg/day fr males after 41 weeks due t severe dermal irritatin) revealed n apparent carcingenic effects when cmpared t vehicle cntrl animals; untreated cntrl animals were nt cmpletely evaluated. Systemic expsure (AUC 0-12h ) at the
7 highest dse was 2 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. Tazartene was fund t be nn-mutagenic in the Ames assay using Salmnella and E. cli and did nt prduce structural chrmsmal aberratins in a human lymphcyte assay. Tazartene was als nn-mutagenic in the CHO/HGPRT mammalian cell frward gene mutatin assay and was nn-clastgenic in the in viv muse micrnucleus test. N impairment f fertility ccurred in rats when male animals were treated fr 70 days prir t mating and female animals were treated fr 14 days prir t mating and cntinuing thrugh gestatin and lactatin with tpical dses f tazartene gel f up t mg/kg/day. Based n data frm anther study, the systemic drug expsure (AUC de ) in the rat wuld be equivalent t 0.31 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 0.38 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. N impairment f mating perfrmance r fertility was bserved in male rats treated fr 70 days prir t mating with ral dses f up t 1 mg/kg/day tazartene, which prduced an AUC de that was 0.95 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 1.2 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. N effect n parameters f mating perfrmance r fertility was bserved in female rats treated fr 15 days prir t mating and cntinuing thrugh day 7 f gestatin with ral dses f tazartene up t 2 mg/kg/day. Hwever, there was a significant decrease in the number f estrus stages and an increase in develpmental effects at 2 mg/kg/day (see CONTRAINDICATIONS). This dse prduced an AUC 0-24h which was 1.7 times that bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 2.1 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. Reprductive capabilities f F1 animals, including F2 survival and develpment, were nt affected by tpical administratin f tazartene gel t female F0 parental rats frm gestatin day 16 thrugh lactatin day 20 at the maximum tlerated dse f mg/kg/day. Based n data frm anther study, the systemic drug expsure (AUC de ) in the rat wuld be equivalent t 0.31 times the AUC 0-24h bserved in psriatic patients treated with 2 mg/cm 2 f tazartene gel 0.1% (extraplated fr tpical applicatin ver a 20% bdy surface area), and 0.38 times the maximum AUC 0-24h in acne patients treated with 2 mg/cm 2 f tazartene gel 0.1% ver a 15% (targeted) bdy surface area. Pregnancy Teratgenic Effects See CONTRAINDICATIONS sectin. Wmen f child-bearing ptential shuld use adequate birth-cntrl measures when TAZORAC Gel is used. The pssibility that a wman f child-bearing ptential is pregnant at the time f institutin f therapy shuld be cnsidered. A negative result fr pregnancy test having a sensitivity dwn t at least 50 miu/ml fr hcg shuld be btained within 2 weeks prir t TAZORAC Gel therapy, which shuld begin during a nrmal menstrual perid. There are n adequate, well-cntrlled studies in pregnant wmen. Althugh there may be less systemic expsure in the treatment f acne f the face alne due t less surface area fr applicatin, tazartene is a teratgenic substance, and it is nt knwn what level f expsure is required fr teratgenicity in humans (see CLINICAL PHARMACOLOGY: Pharmackinetics).
8 Nursing Mthers After single tpical dses f 14 C-tazartene t the skin f lactating rats, radiactivity was detected in milk, suggesting that there wuld be transfer f drug-related material t the ffspring via milk. It is nt knwn whether this drug is excreted in human milk. Cautin shuld be exercised when tazartene is administered t a nursing wman. Pediatric Use The safety and efficacy f TAZORAC Gel have nt been established in pediatric patients under the age f 12 years. Geriatric Use Of the ttal number f subjects in clinical studies f tazartene gels, 0.05% and 0.1% fr plaque psriasis, 163 were ver the age f 65. Subjects ver 65 years f age experienced mre adverse events and lwer treatment success rates after 12 weeks f use f TAZORAC Gel cmpared with thse 65 years f age and yunger. Currently there is n ther reliable clinical experience n the differences in respnses between the elderly and yunger patients, but greater sensitivity f sme lder individuals can nt be ruled ut. Tazartene gel fr the treatment f acne has nt been clinically evaluated in persns ver the age f 65. ADVERSE REACTIONS In human dermal safety studies, tazartene 0.05% and 0.1% gels did nt induce allergic cntact sensitizatin, phttxicity r phtallergy. Psriasis: The mst frequent adverse events reprted with TAZORAC Gel 0.05% and 0.1% were limited t the skin. Thse ccurring in 10 t 30% f patients, in descending rder, included pruritus, burning/stinging, erythema, wrsening f psriasis, irritatin, and skin pain. Events ccurring in 1 t 10% f patients included rash, desquamatin, irritant cntact dermatitis, skin inflammatin, fissuring, bleeding, and dry skin. Increases in psriasis wrsening and sun-induced erythema were nted in sme patients ver the 4th t 12th mnths as cmpared t the first three mnths f a 1 year study. In general, the incidence f adverse events with TAZORAC Gel 0.05% was 2 t 5% lwer than that seen with TAZORAC Gel 0.1%. Acne: The mst frequent adverse events reprted with TAZORAC Gel 0.1% in the treatment f acne ccurring in 10 t 30% f patients, in descending rder, included desquamatin, burning/stinging, dry skin, erythema and pruritus. Events ccurring in 1 t 10% f patients included irritatin, skin pain, fissuring, lcalized edema and skin disclratin. Pstmarketing Experience The fllwing adverse reactins have been identified during pstapprval use f tazartene. Because these reactins are reprted vluntarily frm a ppulatin f uncertain size, it is nt always pssible t reliably estimate their frequency r establish a causal relatinship t drug expsure. Skin and subcutaneus tissue disrders: blister, dermatitis, urticaria, skin exfliatin, skin disclratin (including skin hyperpigmentatin r skin hyppigmentatin), swelling at r near applicatin sites, and pain. OVERDOSAGE Excessive tpical use f TAZORAC Gel may lead t marked redness, peeling, r discmfrt (see PRECAUTIONS: General). TAZORAC Gels 0.05% and 0.1% are nt fr ral use. Oral ingestin f the drug may lead t the same adverse effects as thse assciated with excessive ral intake f Vitamin A (hypervitaminsis A) r ther
9 retinids. If ral ingestin ccurs, the patient shuld be mnitred, and apprpriate supprtive measures shuld be administered as necessary. DOSAGE AND ADMINISTRATION General: Applicatin may cause excessive irritatin in the skin f certain sensitive individuals. In cases where it has been necessary t temprarily discntinue therapy, r the dsing has been reduced t a lwer cncentratin (in patients with psriasis) r t an interval the patient can tlerate, therapy can be resumed, r the drug cncentratin r frequency f applicatin can be increased as the patient becmes able t tlerate the treatment. Frequency f applicatin shuld be clsely mnitred by careful bservatin f the clinical therapeutic respnse and skin tlerance [see Precautins]. Tazrac Gel, 0.05% and 0.1%, are fr tpical use nly. Tazrac Gel, 0.05% and 0.1%, are nt fr phthalmic, ral, r intravaginal use. Avid accidental transfer f Tazrac Gel, 0.05% and 0.1%, int eyes, muth, r ther mucus membranes. If cntact with mucus membranes ccurs, rinse thrughly with water [see Precautins]. Efficacy has nt been established fr less than nce daily dsing frequencies. Fr Psriasis: It is recmmended that treatment start with TAZORAC 0.05% Gel, with strength increased t 0.1% if tlerated and medically indicated. Apply TAZORAC Gel nce a day, in the evening, t psriatic lesins, using enugh (2 mg/cm 2 ) t cver nly the lesin with a thin film t n mre than 20% f bdy surface area. If a bath r shwer is taken prir t applicatin, the skin shuld be dry befre applying the gel. If emllients are used, they shuld be applied at least an hur befre applicatin f TAZORAC Gel. Because unaffected skin may be mre susceptible t irritatin, applicatin f tazartene t these areas shuld be carefully avided. TAZORAC Gel was investigated fr up t 12 mnths during clinical trials fr psriasis. Fr Acne: Cleanse the face gently. After the skin is dry, apply a thin film f TAZORAC Gel 0.1% (2 mg/cm 2 ) nce a day, in the evening, t the skin where acne lesins appear. Use enugh t cver the entire affected area. TAZORAC Gel was investigated fr up t 12 weeks during clinical trials fr acne. HOW SUPPLIED TAZORAC (tazartene) Gel is available in cncentratins f 0.05% and 0.1%. It is available in a cllapsible aluminum tube with a tamper-evident aluminum membrane ver the pening and a white prpylene screw cap, in 30 g and 100 g sizes. TAZORAC Gel 0.05% TAZORAC Gel 0.1% 30 g NDC NDC g NDC NDC Strage: Stre at 25 C (77 F): excursins permitted t C (59-86 F). Revised: 07/ Allergan. All rights reserved. All trademarks are the prperty f their respective wners. Irvine, CA Made in the U.S.A.
10 71722US15
11 PATIENT INFORMATION TAZORAC (TAZ-r-ac) (tazartene) Gel, 0.05% and 0.1% Imprtant infrmatin: TAZORAC Gel is fr use n skin nly. D nt use TAZORAC Gel in yur eyes, muth, r vagina. What is the mst imprtant infrmatin I shuld knw abut TAZORAC Gel? TAZORAC Gel may cause birth defects if used during pregnancy. Females must nt be pregnant when they start using TAZORAC Gel r becme pregnant during treatment with TAZORAC Gel. Fr females wh are able t get pregnant: Yur dctr will rder a pregnancy test fr yu within 2 weeks befre yu begin treatment with TAZORAC Gel t be sure that yu are nt pregnant. Yur dctr will decide when t d the test. Begin treatment with TAZORAC Gel during a nrmal menstrual perid. Use an effective frm f birth cntrl during treatment with TAZORAC Gel. Talk with yur dctr abut birth cntrl ptins that may be used t prevent pregnancy during treatment with TAZORAC Gel. Stp using TAZORAC Gel and tell yur dctr right away if yu becme pregnant while using TAZORAC Gel. What is TAZORAC Gel? TAZORAC Gel 0.05% and 0.1% is a prescriptin medicine used n the skin (tpical) t treat peple with stable plaque psriasis n up t 20% f yur bdy surface. TAZORAC Gel 0.1% is als used n the skin t treat peple with mild t mderate facial acne vulgaris. It is nt knwn if TAZORAC Gel is: safe and effective fr use in children under 12 years f age. effective fr the treatment f acne in peple wh have been treated with retinid medicines r have acne that des nt respnd t treatment with ral antibitics. effective when used less than 1 time a day. safe if used ver mre than 20% f yur bdy fr the treatment f psriasis r acne. Wh shuld nt use TAZORAC Gel? D nt use TAZORAC Gel if yu: are pregnant r plan t becme pregnant. See What is the mst imprtant infrmatin I shuld knw abut TAZORAC Gel? at the beginning f this leaflet. are allergic t tazartene r any f the ingredients in TAZORAC Gel. See the end f this leaflet fr a cmplete list f ingredients in TAZORAC Gel. What shuld I tell my dctr befre using TAZORAC Gel? Befre yu use TAZORAC Gel, tell yur dctr abut all f yur medical cnditins, including if yu: have eczema r any ther skin prblems are breastfeeding r plan t breastfeed. It is nt knwn if TAZORAC Gel passes int yur breast milk. Talk t yur dctr abut using TAZORAC Gel while breastfeeding. Tell yur dctr abut all the medicines yu take, including prescriptin and ver-the-cunter medicines, vitamins, and herbal supplements. Certain medicines, vitamins, r supplements may make yur skin mre sensitive t sunlight. Als, tell yur dctr abut any csmetics yu use, including misturizers, creams, ltins, r prducts that can dry ut yur skin. Hw shuld I use TAZORAC Gel? Use TAZORAC Gel exactly as yur dctr tells yu t use it. Apply TAZORAC Gel 1 time each day, in the evening. D nt get TAZORAC Gel in yur eyes, n yur eyelids, r in yur muth. If TAZORAC Gel gets in r near yur eyes, rinse them well with water. Call yur dctr r get medical help if yu have eye irritatin that des nt g away.
12 Wash yur hands after applying TAZORAC Gel. Fllw these instructins fr applying TAZORAC Gel: If yu have psriasis: If yu shwer r bathe befre applying TAZORAC Gel, yur skin shuld be dry befre applying the gel. Yu may use a cream r ltin t sften r misten yur skin at least 1 hur befre yu apply TAZORAC Gel. Apply a thin layer f TAZORAC Gel t cver nly the psriasis lesins. If yu have acne: Gently wash and dry yur face befre applying TAZORAC Gel. Apply a thin layer f TAZORAC Gel t cver nly the acne lesins. If yu swallw TAZORAC Gel, call yur dctr r g t the nearest hspital emergency rm right away. What shuld I avid while using TAZORAC Gel? Avid sunlight, including sunlamps, during treatment with TAZORAC Gel. TAZORAC Gel can make yu mre sensitive t the sun, and the light frm sunlamps and tanning beds. Yu culd get a severe sunburn. Use sunscreen and wear a hat and clthes that cver yur skin if yu have t be in sunlight. Talk t yur dctr if yu get a sunburn during treatment with TAZORAC Gel. If yu get a sunburn, d nt use TAZORAC Gel until yur sunburn is healed. Avid using csmetics r tpical medicines that may make yur skin mre sensitive t sunlight r make yur skin dry. Avid using TAZORAC Gel n unaffected skin r skin with eczema because it may cause severe irritatin. What are the pssible side effects f TAZORAC Gel? TAZORAC Gel may cause serius side effects, including: Skin irritatin. TAZORAC Gel may cause increased skin irritatin. Tell yur dctr if yu develp itching, burning, redness, r peeling f yur skin during treatment with TAZORAC Gel. If yu develp skin irritatin, yur dctr may tell yu t temprarily stp using TAZORAC Gel until yur skin heals, tell yu t use TAZORAC Gel less ften, r if yu are being treated fr psriasis with the 0.1% strength, may change yur TAZORAC Gel dse. Als, wind r cld weather may be mre irritating t yur skin while yu are using TAZORAC Gel. Sensitivity t sunlight and risk f sunburn. See What shuld I avid while using TAZORAC Gel? The mst cmmn side effects f TAZORAC Gel in peple with plaque psriasis include itching, burning, redness wrsening f psriasis, irritatin and skin pain. The mst cmmn side effects f TAZORAC Gel in peple with acne vulgaris include peeling, burning, dry skin, redness and itching. These are nt all the pssible side effects f TAZORAC Gel. Call yur dctr fr medical advice abut side effects. Yu may reprt side effects t FDA at FDA Hw shuld I stre TAZORAC Gel? Stre TAZORAC Gel at 77 F (25 C). Keep TAZORAC Gel and all medicines ut f the reach f children. General infrmatin abut the safe and effective use f TAZORAC Gel. Medicines are smetimes prescribed fr purpses ther than thse listed in a Patient Infrmatin leaflet. D nt use TAZORAC Gel fr a cnditin fr which it was nt prescribed. D nt give TAZORAC Gel t ther peple, even if they have the same symptms yu have. It may harm them. Yu can ask yur dctr r pharmacist fr infrmatin abut TAZORAC Gel that is written fr health prfessinals. What are the ingredients in TAZORAC Gel? Active ingredient: tazartene Inactive ingredients: ascrbic acid, benzyl alchl, butylated hydrxyanisle, butylated hydrxytluene, carbmer hmplymer type B, edetate disdium, hexylene glycl, plxamer 407, plyethylene glycl 400, plysrbate 40, purified water, and trmethamine Manufactured by: Allergan Sales, LLC., Wac, Texas 2017 Allergan. All rights reserved. All trademarks are the prperty f their respective wners. Irvine, CA Made in the U.S.A.
13 Fr mre infrmatin, call r g t This Patient Infrmatin has been apprved by the U.S. Fd and Drug Administratin Revised: July/ US15
MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP
MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride
More informationMEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP
MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationPATIENT INFORMATION. Rosuvastatin calcium tablets are used along with diet to:
PATIENT INFORMATION Rsuvastatin Calcium (re-soo-va-stat-in KAL-see-um) Tablets Read this Patient Infrmatin carefully befre yu start taking rsuvastatin calcium tablets and each time yu get a refill. If
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationMEDICATION GUIDE. (canagliflozin) Tablets
MEDICATION GUIDE INVOKANA (in-v-kahn-uh) (canagliflzin) Tablets What is the mst imprtant infrmatin I shuld knw abut INVOKANA? INVOKANA can cause imprtant side effects, including: Dehydratin. INVOKANA can
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationMEDICATION GUIDE. Reference ID:
MEDICATION GUIDE GLYXAMBI (glik-sam-bee) (empagliflzin and linagliptin) Tablets Read this Medicatin Guide carefully befre yu start taking GLYXAMBI and each time yu get a refill. There may be new infrmatin.
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationPATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.
PATIENT INFORMATION capsules, fr ral use fr ral suspensin What is TAMIFLU? TAMIFLU is a prescriptin medicine used t: treat the flu (influenza) in peple 2 weeks f age and lder wh have had flu symptms fr
More informationMEDICATION GUIDE. (fingolimod) capsules
MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationMEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?
MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins
More informationPART III: CONSUMER INFORMATION
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationMEDICATION GUIDE. (Interferon alfa-2b)
MEDICATION GUIDE INTRON A (In-trn-aye) (Interfern alfa-2b) Read this Medicatin Guide befre yu start taking INTRON A, and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationMedication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII)
Medicatin Guide MORPHINE SULFATE (mr-pheen) Oral Slutin (CII) IMPORTANT: Keep Mrphine Sulfate Oral Slutin in a safe place away frm children. Accidental use by a child is a medical emergency and can cause
More informationBefore Your Visit: Mohs Skin Cancer Surgery
Befre Yur Visit: Mhs Skin Cancer Surgery Yur Kaiser Permanente Care Instructins Skin Cancer Infrmatin What is skin cancer? Skin cancers are tumrs, r malignancies, f the skin. Skin cancer is assciated with
More informationCONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS
CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS Yu want t take teststerne t masculinize yur bdy. Befre taking it, there are several things yu need t knw abut. They are the pssible advantages, disadvantages,
More informationIf you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Bayer plc Bayer Huse Strawberry Hill Newbury Berkshire RG14 1JA United Kingdm Telephne: +44 (0)1635 563 000 Facsimile: +44 (0)1635 563 393 Cmpany Web Site: http://www.bayer.c.uk Due t regulatry changes,
More informationRead all of this leaflet carefully before you start taking this medicine.
Due t regulatry changes, the cntent f the fllwing Patient Infrmatin Leaflet may vary frm the ne fund in yur medicine pack. Please cmpare the 'Leaflet prepared/revised date' twards the end f the leaflet
More information454-8 (Insert) MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place
MEDICATION GUIDE ZUBSOLV (Zub-slve) (buprenrphine and nalxne) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away frm children. Accidental use by a child is a medical emergency and
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationPercutaneous Nephrolithotomy (PCNL)
Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More information/0515 Medication Guide Aripiprazole Tablets
8415721/0515 Medicatin Guide Aripiprazle Tablets (air-eh-pip-rah-zle) Read this Medicatin Guide befre yu start taking aripiprazle tablets and each time yu get a refill. There may be new infrmatin. This
More informationHead and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth.
DENTAL EXTRACTION This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins that
More informationMEDICATION GUIDE XARELTO (zah-rel-toe) (rivaroxaban) tablets
MEDICATION GUIDE XARELTO (zah-rel-te) (rivarxaban) tablets Read this Medicatin Guide befre yu start taking XARELTO and each time yu get a refill. There may be new infrmatin. This Medicatin Guide des nt
More informationMEDICATION GUIDE Levofloxacin (lee-voe-flox-a-sin) Tablets, USP 250 mg Tablets, 500 mg Tablets, and 750 mg Tablets
MEDICATION GUIDE Levflxacin (lee-ve-flox-a-sin) Tablets, USP 250 mg Tablets, 500 mg Tablets, and 750 mg Tablets Read this Medicatin Guide befre yu start taking levflxacin tablets and each time yu get a
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationPATIENT INFORMATION. (methotrexate) injection, for subcutaneous use
What is Rasuv? PATIENT INFORMATION RASUVO (ruh-soo-vh) (methtrexate) injectin, fr subcutaneus use Rasuv is a single-dse manually-triggered aut-injectr cntaining a prescriptin medicine, methtrexate. Methtrexate
More informationMEDICATION GUIDE QSYMIA (Kyoo sim ee uh) (phentermine and topiramate extended-release) Capsules CIV
MEDICATION GUIDE QSYMIA (Ky sim ee uh) (phentermine and tpiramate extended-release) Capsules CIV Read this Medicatin Guide befre yu start taking Qsymia and each time yu get a refill. There may be new infrmatin.
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationTendon problems can happen in people of all ages who take levofloxacin. Tendons are tough cords of tissue that connect muscles to bones.
Medicatin Guide LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION, 25 mg/ml and LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION in 5% Dextrse fr Intravenus Use Read this Medicatin Guide befre yu start taking levflxacin
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationThese are medical emergencies that can cause death. If possible, remove OTFC from the mouth.
MEDICATION GUIDE Oral Transmucsal Fentanyl Citrate (OTFC) CII (fentanyl citrate) ral transmucsal lzenge 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg IMPORTANT: D nt use Oral Transmucsal Fentanyl
More informationRoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation
RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits
More informationPACKAGE LEAFLET INFORMATION FOR THE PATIENT
PACKAGE LEAFLET INFORMATION FOR THE PATIENT AMPICILLIN 125mg/5ml and 250mg/5ml ORAL SUSPENSION Please read all f this leaflet carefully befre yu start taking this medicine because it cntains imprtant infrmatin
More informationMedication Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets
Medicatin Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets IMPORTANT: D nt use ABSTRAL unless yu are regularly using anther piid pain medicine arund-the-clck fr at least ne week r lnger fr yur
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationMedication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection
Medicatin Guide SIGNIFOR [sig-na-fr] (pasiretide) Injectin Read this Medicatin Guide befre yu start using SIGNIFOR and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take
More informationPackage leaflet: Information for the user. GASTROGRAFIN GASTROENTERAL SOLUTION Sodium amidotrizoate and meglumine amidotrizoate
Due t regulatry changes, the cntent f the fllwing Patient Infrmatin Leaflet may vary frm the ne fund in yur medicine pack. Please cmpare the 'Leaflet prepared/revised date' twards the end f the leaflet
More informationBedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:
Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign
More information9200 Calumet Avenue Sincer Jacob, PA-C Munster, IN Jessica Morin, ATC Deanna Cozzi, ATC
DISCHARGE INSTRUCTIONS & PHYSICAL THERAPY PROTOCOL: Subacrmial Decmpressin, Glenhumeral Debridement, Distal Clavicle Resectin Recvery after shulder arthrscpy entails cntrlling swelling and discmfrt, return
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationPackage leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Slutin fr injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More informationCONSUMER MEDICINE INFORMATION
CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers sme cmmn questins abut CEFTRIAXONE lcp. It des nt cntain all the available infrmatin. It des nt take the place f talking t yur
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet n Lichen Planus Intrductin Lichen planus (LP) is a disease f the skin and/r mucus membranes that resembles lichen. A lichen is a cmpsite rganism that emerges
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationNew Zealand Consumer Medicine Information. Tramadol hydrochloride immediate release capsules (50 mg) and solution for injection (50 mg/ml, 100 mg/2ml)
New Zealand Cnsumer Medicine Infrmatin TRAMAL Tramadl hydrchlride immediate release capsules (50 mg) and slutin fr injectin (50 mg/ml, 100 mg/2ml) What is in this leaflet Please read this leaflet carefully
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationPackage leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationAsthma inhalers, medicines and treatments
Asthma inhalers, medicines and treatments Reliever inhalers Yur Emergency Rescue Reliever Everyne with asthma shuld ALWAYS carry a reliever (blue inhaler) inhaler at all the time s it s n hand in an emergency
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationFlu Season Key Points ( )
2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...
More informationSuicidal thoughts or actions:
MEDICATION GUIDE Venlafaxine (VEN la fax een) Hydrchlride Extended-release Capsules USP Read the Medicatin Guide that cmes with venlafaxine hydrchlride extended-release capsulesbefre yu start taking them
More informationFrequently asked questions: Influenza A (H1N1)v
July 30 th 2009 V1.0 Frequently asked questins: Influenza A (H1N1)v (Swine Flu) infrmatin fr parents The fllwing advice is fr parents f children in all educatinal institutins, including crèches, childcare,
More informationo New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe.
MEDICATION GUIDE FLUOXETINE CAPSULES, USP (fl xʹ e teen) 10 mg and 20 mg Read the Medicatin Guide that cmes with fluxetine capsules befre yu start taking it and each time yu get a refill. There may be
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for Sublingual or Buccal Administration (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX wn) (buprenrphine and nalxne) Sublingual Film fr Sublingual r Buccal Administratin (CIII) IMPORTANT: Keep SUBOXONE sublingual film in a secure place away frm children.
More informationPackage leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate
Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant
More informationInitial Postoperative Knee Care Patella or Quadriceps Tendon Repairs: - Videos are available on Dr. Witty s website: drjeffreywitty.
Initial Pstperative Knee Care Patella r Quadriceps Tendn Repairs: - Vides are available n Dr. Witty s website: drjeffreywitty.cm Imprtant Phne Numbers: - Please see the cntact infrmatin abve fr imprtant
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationPatrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction Surgery Instructions Hip
Patrick J McGahan, MD Orthpaedic Surgen Specializing in Sprts Medicine/Shulder Recnstructin 2801 K St, Ste 330, Sacrament, CA, 95816 (p) 916-733-5049 (f) 916-733-8914 www.patrickmcgahanmd.cm Befre Surgery
More informationAdult Preventive Care Guidelines
Adult Preventive Care Guidelines Gundersen is yur partner fr better health. We want t wrk with yu t make sure that yu and yur family are as healthy as pssible. That can be accmplished best if we wrk tgether
More informationI am having a Rotator Cuff Repair
I am having a Rtatr Cuff Repair A rtatr cuff repair is surgery t repair a trn tendn in the shulder. The rtatr cuff is a grup f muscles and tendns that frm a cuff ver the shulder jint. The muscles and tendns
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationCIPRODEX (ciprofloxacin and dexamethasone), otic suspension Initial U.S. Approval: 2003
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights d nt include all the infrmatin needed t use CIPRODEX safely and effectively. See full prescribing infrmatin fr CIPRODEX CIPRODEX (ciprflxacin and
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationAdvantage EAP Employee Assistance Program
Advantage EAP Emplyee Assistance Prgram July 2014 In This Issue What might we face? Symptms f SAD Seasnal changes in biplar disrder Tips fr cmbating summer truble When t seek help Tips fr helping thse
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Prduct Summary 1. Trade Name f the Medicinal Prduct Betnvate Cream 2. Qualitative and Quantitative Cmpsitin Betamethasne Valerate 0.122% W / W Excipients with knwn effect:
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationPHARYNGO-OESOPHAGECTOMY
PHARYNGO-OESOPHAGECTOMY This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationDosage Administration
Pharmacy Technician Dsage Administratin Dsage Administratin Dsage Frms and Their Usages Medicatins ften cnsist f small quantities f active ingredients cmbined with inactive ingredients t create varius
More informationRisk factors in health and disease
Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk
More informationTo remind workers that contact with poison oak can cause skin irritations. To educate workers about how to recognize poison oak.
Safety Training Tpic Purpse f Meeting T remind wrkers that cntact with pisn ak can cause skin irritatins. T educate wrkers abut hw t recgnize pisn ak. T cnsider ways t prtect yurself frm skin irritatins
More informationBLOOD BORNE PATHOGENS
BLOOD BORNE PATHOGENS GALVESTON ISD ANNUAL TRAINING 2018-2019 Galvestn Independent Schl District Special Prgrams/ECH Health Services Required Training Ò Training is required by the Texas Department f Health
More informationAppendix 1 Example of Homely Remedy Policy
Appendix 1 Example f Hmely Remedy Plicy Hmely Remedy Plicy - EXAMPLE This plicy applies t (insert name f Care Hme) Definitin A hmely (r husehld) remedy is a medicinal prduct fr the shrt-term treatment
More informationZika Virus. Where has Zika virus been found? Zika in the United States and its territories:
Where has Zika virus been fund? Zika Virus Prir t 2015, Zika virus utbreaks have ccurred in areas f Africa, Sutheast Asia, and the Pacific Islands. In May 2015, the Pan American Health Organizatin (PAHO)
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationTreatment Guidelines June 2013, D0028 Rev. F
Treatment Guidelines June 2013, D0028 Rev. F Cutera Inc. Wrld Headquarters 3240 Bayshre Bulevard, Brisbane, CA 94005 USA Tel: +1 415 657 5500 Fax: +1 415 330 2444 www.cutera.cm June 2010, D0028 Rev. F
More informationDIABETES AND PANCREATIC EXOCRINE INSUFFICIENCY
YOU AND YOUR BODY DIABETES AND PANCREATIC EXOCRINE INSUFFICIENCY kk WHY IS THIS LEAFLET FOR YOU? Pancreatic excrine insufficiency (PEI) is imprtant t understand in diabetes care due t the changing functins
More informationFOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES
Appendix h STUDY NUMBER: COST OF UNSAFE ABORTION FOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES T be administered abut 2-3 weeks after leaving the health facility 1. IDENTIFICATION 101. Patient identificatin
More informationThe principles of evidence-based medicine
The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t
More information